DiscoverThe Top Line
The Top Line
Claim Ownership

The Top Line

Author: Fierce Life Sciences

Subscribed: 199Played: 8,299
Share

Description

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

295 Episodes
Reverse
Clinical trial teams face a difficult balance: preserve scientific rigor while making protocols feasible for sites and participants. In this sponsored episode of The Top Line, host Kelly Hogan speaks with Metta Anderson, general manager of data analytics and insights at WCG, about how protocol burden affects enrollment timelines and trial performance. Anderson discusses how generative AI and large language models can extract structured information from complex protocol documents, enabling data-driven comparisons with other protocols and standard of care. She shares findings from a WCG study of about 1,000 protocols and enrollment rates across 109,000 sites, including the impact of participant and site burden on enrollment timelines. The conversation also explores why teams should critically evaluate procedures, visits, endpoints and data that may not be essential to the trial’s critical path. Their conversation explores how burden scoring, strong data foundations and subject matter expertise can help teams design more efficient trials, reduce amendment risk and better respect the time of sites and participants.See omnystudio.com/listener for privacy information.
Gate Bioscience is betting that a decades-old biological mechanism could pave the way for a new class of medicines. The biotech is developing small molecules that selectively block disease-causing proteins from passing through a cellular channel called Sec61, causing them to be degraded before they can do harm. The approach could be particularly promising for diseases of the brain, where traditional biologics face significant delivery challenges. Gate's first publicly disclosed program targets prion disease, but the company sees opportunities across inflammation, fibrosis and other therapeutic areas. In this episode of "The Top Line," Fierce Biotech's Marissa Russo sits down with Gate co-founder and CEO Jordi Mata-Fink, Ph.D., to discuss the science behind the technology, how an expanded partnership with Eli Lilly is helping advance the platform and what's next as Gate prepares to move its first molecular gate drugs into the clinic. To learn more about the topics in this episode:  Gate CEO sees expanded $870M pact with Lilly as ‘vote of confidence’ in biotech’s platform See omnystudio.com/listener for privacy information.
Patient experience is shaped by more than clinical care. It begins with transportation, parking and wayfinding, and continues through check-in, the patient room, diagnostics and follow-up. In this sponsored episode of Podnosis, host Irena Luo speaks with Candace LeVaughn, industry principal of healthcare at Schneider Electric, and Debbie Gregory, principal healthcare innovation consulting at SSR, about designing and operating healthcare environments that better support patients and caregivers. The discussion examines often-unseen pressures, including nursing shortages, workplace violence, burnout, facilities staffing gaps, aging infrastructure and disconnected technologies that create delays and workarounds. The guests explore how robotics, wearables, building automation, interoperable platforms and data analytics can improve reliability and make care delivery more seamless. They also consider the next five years of healthcare design, from AI and ambient intelligence to automated transportation, power demands and grid constraints. They share why healthcare organizations should take an ecosystem-wide approach, test solutions with end users and include clinicians, staff and patients in decisions that shape the care environment.See omnystudio.com/listener for privacy information.
Broad chronic kidney disease labels can obscure distinct biology, complicating patient selection, progression assumptions and treatment-signal interpretation. In this sponsored episode of The Top Line, Will Hurth speaks with Dr. Ronen Schneider, medical director of renal genetics at Natera, about the business and development implications of moving toward genotype-defined kidney disease.  Schneider explains how RenasightIQ connects genetic test results with clinical intake data, longitudinal laboratory measures and claims data from more than 300,000 patients. He discusses findings across FSGS and genetically defined glomerular disease, including differences in progression to end-stage kidney disease.  The conversation translates those insights into considerations for drug-development teams: natural-history modeling, endpoint selection, prognostic enrichment, background therapy and patient recruitment. Schneider also outlines questions teams can apply to completed studies, ongoing trials and screening populations to evaluate genetic causes, placebo-arm progression and potential variation in treatment effect. Listen to the podcast to learn how real-world genetic data can help expose hidden heterogeneity and strengthen clinical development strategy. See omnystudio.com/listener for privacy information.
China can play several roles in a global clinical development program, from supporting a capital-efficient proof-of-concept study to contributing evidence within a multiregional clinical trial. In this sponsored episode of The Top Line, Caidya Chief Operating Officer Mike Clay and Vice President of Business Development Jinye Shen join Fierce Life Sciences’ Will Herth to discuss how sponsors can decide when and how to include China.  The conversation examines China-only, multiregional and sequenced development approaches, and how the intended use of China-generated evidence should shape the strategy. They also explain why a large patient population does not automatically equal recruitable patients, highlighting the importance of site-level feasibility, investigator networks, local treatment practices, competing trials and referral pathways.  Additionally, they discuss the risks of considering China too late, including protocol redesign, duplicated work, delayed trial starts and reduced regulatory flexibility. This conversation assesses practical perspectives on regulatory planning, bridging-study questions, operational execution, governance, data quality and the balance between local expertise and global accountability. See omnystudio.com/listener for privacy information.
loading
Comments